Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: The influence of hydrogen bond donors on extravascular transport and antitumor activity

Journal of Medicinal Chemistry

Volumn 50, Issue 26, 2007, Pages 6654-6664

  Hay, Michael P ^a   Pchalek, Karin ^a,b   Pruijn, Frederik B ^a   Hicks, Kevin O ^a   Siim, Bronwyn G ^a,c   Anderson, Robert F ^a   Shinde, Sujata S ^a   Phillips, Victoria ^a,d   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Magdalen Centre   (United Kingdom)

^d University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; 6 MORPHOLINOPROPYLOXY 1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; HYDROGEN; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION COEFFICIENT; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HYPOXIC CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLIC N-OXIDES; DIFFUSION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN BONDING; MICE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; TUMOR STEM CELL ASSAY;

EID: 37349056730     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701037w     Document Type: Article

References (46)

1. Evans, S. M.; Koch, C. J. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003, 195, 1-16, and references therein.
2. Harris, A. L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47.
3. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67.
4. Pennachietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3, 347-361.
5. Cairns, R. A.; Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 2004, 64, 2054-2061.
6. Subarsky, P.; Hill, R. P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastases 2003, 20, 237-250.
7. Durand, R. E. The influence of microenvironmental factors during cancer therapy. In Vivo 1994, 8, 691-702.
8. Tannock, I. F. Conventional cancer therapy: promise broken or promise delayed. Lancet 1998, 351 (Suppl 2), 9-16.
9. Brown, J. M.; Wilson, W. R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
10. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41, 31-39.
11. Fyles, A. W.; Milosevic, M.; Wong, R.; Kavanagh, M. C.; Pintilie, M.; Sun, A.; Chapman, W.; Levin, W.; Manchul, L.; Keane, T. J.; Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 1998, 48, 149-156.
12. Koukourakis, M. I.; Bentzen, S. M.; Giatromanolaki, A.; Wilson, G. D.; Daley, F. M.; Saunders, M. I.; Dische, S.; Sivridis, E.; Harris, A. L. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 2006, 24, 727-735.
13. Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 1996, 74, S32-S38.
14. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
15. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 1993, 67, 1163-1170.
16. Denny, W. A.; Wilson, W. R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Invest. Drugs 2000, 9, 2889-2901.
17. Patterson, A. V.; Saunders, M. P.; Chinje, E. C.; Patterson, L. H.; Stratford, I. J. Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Des. 1998, 13, 541-573.
18. Anderson, R. F.; Shinde, S. S.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 2003, 125, 748-756.
19. Shinde, S. S.; Anderson, R. F.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J. Am. Chem. Soc. 2004, 126, 7853-7864.
20. Wang, J.; Biedermann, K. A.; Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992, 52, 4473-4477.
21. Sum, B. G.; van Zijl, P. L.; Brown, J. M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer 1996, 73, 952-960.
22. Sum, B. G.; Menke, D. R.; Dorie, M. J.; Brown, J. M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997, 57, 2922-2928.
23. Siim, B. G.; Pruijn, F. B.; Sturman, J. R.; Hogg, A.; Hay, M. P.; Brown, J. M.; Wilson, W. R. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res. 2004, 64, 736-742.
24. Brown, J. M; Wang, L. H. Tirapazamine: laboratory data relevant to clinical activity. Anti-Cancer Drug Des. 1998, 13, 529-539.
25. Marcu, L.; Olver, I. Tirapazamine: From bench to clinical trials. Curr. Clin. Pharmacol. 2006, 1, 71-79.
26. Doherty, N.; Hancock, S. L.; Kaye, S.; Coleman, C. N.; Shulman, L.; Marquez, C.; Mariscal, C.; Rampling, R.; Senan, S.; Roemeling, R. V. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 379-382.
27. Rishin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; Hart, R.; Sexton, M.; D'Costa, I.; von Roemeling, R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 535-542.
28. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen, M.; Jackson, M.; Kenny, L.; Penniment, M.; Corry, J.; Lamb, D.; McClure, B. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, 23, 79-87.
29. Le, Q.-T.; Taira, A.; Budenz, S.; Dorie, M. J.; Goffinet, D. R.; Fee, W. E.; Goode, R.; Bloch, D.; Koong, A.; Brown, J. M.; Pinto, H. A. Mature results from a randomized phase II trial of cisplatin plus 5-fluouracil and radiotherapy with or without tirapazamine in patients with respectable stage IV head and neck squamous cell carcinomas. Cancer 2006, 106, 1940-1949.
30. Durand, R. E.; Olive, P. L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Invest. 1997, 5, 213-219.
31. Durand, R. E.; Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 689-692.
32. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 641-649.
33. Kyle, A. H.; Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213-220.
34. Baguley, B. C.; Hicks, K. O.; Wilson, W. R. Tumour cell cultures in drug development. In Anticancer Drug Development; Baguley, B. C., Kerr, D. J., Eds.; Academic Press: San Diego, 2002; pp 269-284.
35. Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in multicellular layers. Cancer Res. 2003, 63, 5970-5977.
36. Hicks, K. O.; Siim, B. G.; Pruijn, F. B.; Wilson, W. R. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat. Res. 2004, 161, 656-666.
37. Hicks, K. O.; Pruijn, F. B.; Secomb, T. W.; Hay, M. P.; Hsu, R.; Brown, J. M.; Denny, W. A.; Dewhirst, M. W.; Wilson, W. R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 2006, 98, 1118-1128.
38. Hicks, K. O.; Myint, H.; Patterson, A. V.; Pruijn, F. B.; Siim, B. G.; Patel, K.; Wilson, W. R. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 560-571.
39. Pruijn, F. B.; Sturman, J.; Liyanage, S.; Hicks, K. O.; Hay, M. P.; Wilson, W. R. Extravascular transport of drugs in tumor tissue: Effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J. Med. Chem. 2005, 48, 1079-1087.
40. Hay, M. P.; Hicks, K. O.; Pruijn, F. B.; Pchalek, K.; Siim, B. G.; Wilson, W. R.; Denny, W. A. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J. Med. Chem. [Online early access]. DOI: 10.1021/jm070670g. Published online: November 15, 2007. http://pubs.acs.org/cgi-bin/asap.cgi/jmcmar/asap/html/jm070670g.html.
41. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Pruijn, F. B.; Anderson, R. F.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 2003, 46, 169-182.
42. Kelson, A. B.; McNamara, J. P.; Pandey, A.; Ryan, K. J.; Dorie, M. J.; McAfee, P. A.; Menke, D. R.; Brown, J. M.; Tracy, M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des. 1998, 13, 575-592.
43. Hay, M. P.; Denny, W. A. A new and versatile synthesis of 3-alkyl-1,2,4-benzotriazine-1,4-dioxides: preparation of the bioreductive cytotoxins SR4895 and SR4941. Tetrahedron Lett. 2002, 43, 9569-9571.
44. Pchalek, K.; Hay, M. P. Stille coupling reactions in the synthesis of hypoxia-selective 3-alkyl-1,2,4-benzotriazine 1,4-dioxide anticancer agents. J. Org. Chem. 2006, 71, 6530-6535.
45. Siim, B. G.; Hicks, K. O.; Pullen, S. M.; van Zijl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs - cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
46. Patel, K. B.; Willson, R. L. Semiquinone free radicals and oxygen. Pulse radiolysis study of one electron equilibria. J. Chem. Soc. Faraday Trans. 1973, 69, 814-819.